Table 1 Study characteristics of included trials
Trial name | Publication year | Recruitment period | No. of centers | Patients characteristic | Follow-up (w) | Randomized patients | Age (Year)a | Female n(%) | Duration of RA (year) | Background therapy | Control | Baricitinib |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RA-BEAM [28] | 2017 | 2012.11–2014.09 | 281 | Active RA patients had an inadequate response to methotrexate | 24~52 | 1307 | 53 .4 (6.3) | 1008 (71) | 10 | MTX | Placebo | 4 mg, qd |
RA-BEGIN [29] | 2017 | 2013.01–2014.08 | 198 | RA patients who received no prior DMARDs therapy | 24~52 | 588 | 50.2 (13.4) | 425 (72) | 1.3~1.9 | Non | Placebo | 4 mg, qd |
BRA-BUILD [30] | 2016 | 2013.01–2014.05 | 182 | RA patients who had insufficient response or intolerance to ≥1 DMARDs | 12~24 | 684 | 51 (12) | 557 (81) | 8 | Any DMARD | Placebo | 2 mg and 4 mg, qd |
RA-BEACON [31] | 2016 | 2013.01–2014.03 | 178 | RA patients who had insufficient response or intolerance to ≥1 DMARDs | 12~24 | 527 | 56 (11) | 431 (82) | 14 | Any DMARD | Placebo | 2 mg and 4 mg, qd |
NCT01469013 [32] | 2016 | 2011.11–2013.12 | 24 | RA patients with stably using of MTX | 12 | 145 | 53.7 (12) | 118 (81) | 5~6.3 | MTX | Placebo | 1 mg, 2 mg, 4 mg and 8 mg, qd |
NCT01185353 [33] | 2015 | 2010.10–2012.02 | 69 | RA patients with regularly using of MTX | 12 | 301 | 53.3 (11.7) | 249 (83) | 5.3~6.6 | Any DMARD | Placebo | 1 mg, 2 mg, 4 mg and 8 mg, qd |